According to a new market report published by Transparency Market Research  "Neuromodulation Devices Market - Global Industry Analysis, Size, Share and Forecast, 2012 - 2018," the global neuromodulation devices market was valued at USD 2,758 million in 2011 and is expected to grow at a CAGR of 14.4% from 2012 to 2018, to reach an estimated value of USD 7,072.6 million by 2018.

The market is driven by factors such as the aging world population leading to chronic diseases such as Parkinson's and Alzheimer's disorders and technological advancements in the field of neuromodulation devices including the invention of transdermal neuromodulation technology by NMT (Neurowave Medical Technologies). Moreover, the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, the availability of external funding to conduct clinical studies to help come up with new and technologically advanced products and the rising healthcare related consumer expenditure have also driven the growth in this market. The fact that a neuromodulation device could be used as an add-on treatment and so can be used simultaneously with other medications also drives the market forward.

The North American region holds majority of the market share and accounted for a share of 65% in 2011. The North American neuromodulation device market was valued at USD 1,792.7 million in 2011. The economic developments in the Asia Pacific region make it the fastest growing region (CAGR of more than 15% from 2012 to 2018) in the neuromodulation devices market.

The future growth of the market will be ensured by capitalizing on market opportunities such as increasing healthcare related consumer expenditure in emerging economies in the Asia Pacific, Latin American and Eastern European regions. The availability of medical device manufacturing outsourcing options helps in curbing costs and thereby enhances profit margins. Also, the presence of consolidation options in the healthcare industry helps in strengthening the revenue base to conduct R&D exercises for new product development and thus helps in strengthening market share.

Implementation of the Affordable Healthcare for America Act, 2010 which imposes an excise tax of 2.5% on medical devices and the stringent FDA regulations are some of the factors restraining the growth of the market. Risks involved in using a neuromodulation device such as injury to the vagus nerve and nearby blood vessels (carotid artery and jugular vein) in case of a vagus nerve pacemaker also impedes the growth of the market.

Neuromodulation Devices Market by Technology

• Spinal Cord Stimulation Devices
• Deep Brain Stimulation Devices
• Vagus Nerve Stimulation Devices
• Sacral Nerve Stimulation Devices
• Gastric Electric Stimulation Devices

Neuromodulation Systems for Different Application Areas

• Medtronic's Spinal Cord and Deep Brain Neurostimulation Systems
• St. Jude Medical's Eon  Mini Neurostimulator System
• Boston Scientific's Precision Spinal Cord Stimulation System
• Nevro's Senza System for Spinal Cord Stimulation
• Cyberonics' VNS Therapy System
• Codman & Shurtleff's Medstream system
• Medtronic's Enterra™ Therapy System
• IntraPace's abiliti system

Neuromodulation Devices Market by Geography

• North America
• Europe
• Asia Pacific
• RoW (Rest of the World)

» Read More...

According to a new market report published by Transparency Market Research "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018," the global CINV market was worth USD 1.3 billion in 2011 and is expected to reach USD 2.1 billion in 2018, growing at a CAGR of 7.1% from 2013 to 2018. The North American CINV existing and pipeline drugs market is expected to reach USD 1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these 

regions.

Nausea and vomiting represent the most frequent side-effects experienced by chemotherapy patients, referred to as chemotherapy-induced nausea and vomiting (CINV) Market, which is debilitating to cancer patients. Emetogenic refers to the likelihood of a chemotherapy drug affecting the patient in an adverse manner, leading to added illness or sickness. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 30-90% of the cases.

Current drug treatments available to prevent CINV have failed to completely overcome the symptoms of this disease. Moreover, most of the drugs are approved for acute-onset CINV whereas there is no drug approved yet for delayed-onset CINV for patients receiving HEC, which occurs more frequently (50-70% of patients) in the cancer population.

The inefficiency to effectively predict CINV incidence and understand the complex physiology of CINV by healthcare providers coupled with the failure to adhere to recommended guidelines, have been prominent reasons for deficiency in CINV treatment.However, the current pipeline in the CINV market offers huge potential to overcome such unmet needs, with better and efficient drugs for both acute and the more prominent, delayed-onset CINV.

Netu-palo FDC of Helsinn Healthcare, currently in phase III trials, which was in-licensed by the Helsinn group from Roche in the year 2005, helps in preventing CINV in acute as well as delayed-onset CINV patients. Due to its combination of a 5-HT3 antagonist and an NK-1 antagonist, the netu-palo FDC helps in overcoming unmet needs existing with current drug treatments available, which are mostly 5-HT3 antagonists. Moreover, other drugs in the pipeline, namely, APF530 and rolapitant offer physicians alternative treatment options for patients who show little relief from existing drugs in the market.

This research is specially designed to estimate and analyze the demand and performance of the CINV pipeline drugs in a global scenario. The research provides in-depth analysis of CINV pipeline drugs manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global CINV pipeline drugs market and provides detailed analysis, historical data and statistically refined forecast for the segments covered. 

The study presents a comprehensive assessment of the stakeholder strategies, winning imperatives for them by segmenting the global CINV pipeline drugs market as below:

• CINV - Pipeline Products APF530 (long-acting granisetron - 5-Ht3RA)
• Efficacy Results of APF530 MEC Phase III Study
• Efficacy Results of APF530 HEC Phase III Study Rolapitant (NK-1-RA)
• Chemical structure of rolapitant
• Netupitant-Palonosetron FDC
• Introduction
• Mechanism of action
• Chemical structure of netupitant
• Unmet Needs in the CINV Market
• Clinical Trial Details for CINV pipeline drugs APF530
• Clinical Trial: ID- NCT00343460 Rolapitant
• Clinical Trial: ID - NCT01500226
• Clinical Trial: ID - NCT01500213
• Clinical Trial: ID - NCT01499849 Netupitant-palonosetron FDC
• Clinical Trial: ID - NCT01376297
• Clinical Trial: ID - NCT01339260

In addition the report provides a cross-sectional analysis of all the above segments with respect to the following geographical markets:

• North America
• Europe

» Read More...

According to a new market report "Bioinformatics Market - Global Industry Size, Market Share, Trends, Analysis and Forecast, 2012 - 2018," published by Transparency Market Research, the global bioinformatics market is estimated to reach market size worth USD 9.1 Billion in 2018. The market is forecasted to record double digit growth, with highest revenue contribution from the bioinformatics platforms segment.

The global bioinformatics market, estimated at USD 2.3 billion in 2012 is forecasted to reach a market size of USD 9.1 billion in 2018, at a CAGR of 25.4% from 2012 - 2018. The market growth is driven by rise in applications across various industries. The key contribution to the market demand is from fields such as agriculture biotechnology, pharmaceutical research and development, medical and clinical diagnostics, and other life-sciences related industries.

The bioinformatics platform holds the largest market share and is estimated to account for nearly 50% of the market revenue. The services market currently holds a relatively smaller market share, however is expected to increase considerably over the forecast period. The bioinformatics platform segment is the fastest growing market and is expected to contribute 54% of the total market growth during the same period.

The demand across genomics and wide application in the medical and biological information sector is driving the demand for bioinformatics platforms and services in the global market. The research outsourcing by pharmaceutical giants in the fields involving bioinformatics content is a significant driver of the global bioinformatics market. These companies in efforts to reduce time and cost on R&D activities involved in the development of novel drugs and new applications for existing drugs, are looking for outsourcing services for bioinformatics knowledge and management tools, platforms, and services.

Among the regional markets, North America holds the largest share; however, is forecasted to be succeeded by Europe as the leading market share holder in 2018, due to fast growth shown by major European markets such as Germany and U.K. Europe is forecasted to be the fastest growing region, with growth mainly driven by rising government support for R&D activities in the region. The bioinformatics services market in Europe and North America is well developed and organized whereas it is still in initial growth stage in emerging markets of Asia Pacific region.

The report analyzes the global bioinformatics market growth across various segments such as knowledge management tools, platforms, and services. The in-depth analysis includes analysis of sub-segments up to three levels, with cross sectional analysis on the basis of geographical and regional market size and forecasts. The cross-sectional analysis of the global bioinformatics market based on applications further provides market growth potential across various end user industries. The segments considered on the basis of application are - molecular medicine, gene therapy, drug development and preventive medicine.

» Read More...

According to a new market report published by Transparency Market Research, "Biotechnology Market by Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), by Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2010 - 2017," the global market for biotechnology was valued at USD 216.5 billion in 2011 and is expected to reach USD 414.5 billion in 2017, growing at a CAGR of 11.6% from 2012 to 2017.

The biotechnology market is expected to show substantial growth over the forecast period owing to the government support offered to various companies operating in the biotechnology field. In addition, the increased demand for food in developing countries has spurred growth of the bioagriculture market. Bioseeds are expected to show exponential growth as compared to conventional seeds over the forecast period.

Biopharmaceuticals dominated the global market, accounting for over 60% of the overall revenue in 2011. Bioservice applications are expected to register the fastest growth due to the operating cost benefits associated with emerging economies, particularly in terms of raw materials, labor and regulatory support.

Outsourcing of clinical trials, contract manufacturing and drug discovery has emerged as a key trend in developed countries, leading to the growth of the bioservices industry in the developing economies of India, Thailand, Malaysia and China. The developing countries provide superior research and trial facility at lower cost. The market for bioagriculture applications, including bioseeds, is expected to reach USD 27.46 billion in 2018.

North America dominated the global market, accounting for over 42% of the overall biotechnology revenue in 2011. With increasing focus on renewable chemicals, Asia Pacific is expected to be the fastest growing regional market, at an estimated CAGR of 14.1% from 2012 to 2017.

Key players in the biotechnology market include Roche, Amgen, Novo Nordisk, Sanofi, Pfizer and Novartis. The detailed profile of these companies along with a global company market share analysis has been included in the report.z

The biotechnology market has been analyzed in detail and revenues generated by every application in regions such as Europe, North America, Asia Pacific and RoW have been included.

» Read More...

Mobile acceleration is a set of processes that help increase the speed with which applications can be accessed on a mobile phone. Mobile acceleration applications include online games and transactions. It offers improved user experience, reduction of complex features, and increased revenues. This technology is designed to speed up web content, mobile and network applications, and for streamlining the web. The market is spurred by increasing mobile gadget users, worldwide data consumption, and desktop users switching to mobile based platforms. The mobile acceleration market is segmented based on various types such as mobile devices, mobile acceleration types, mobile applications and mobile content.  

The mobile acceleration market can be segmented as follows:

By mobile device type:

• Tablets
• Smart phones
• Other devices

By mobile acceleration types:

• WAN optimization
• Device Acceleration
• Web/Content Acceleration
• Mobile Content Delivery Network (CDN) Acceleration
• Other Accelerations

By mobile content types:

• Gaming Content
• Software updates
• Image & Music Content
• Other Content

By mobile application types:

• Social Networking Apps
• Gaming Apps
• M-Commerce Apps
• Music & Messaging Apps
• Location Based Service Apps
• Other Apps

The mobile acceleration market presents many opportunities as number of tech savvy users are increasing, thus forming a potential market for the vendors. Network solution providers and wireless service providers will be affected by the growth of the mobile acceleration market. 

Some of the  market players in the mobile acceleration market include  F5 Networks Inc., Riverbed Technology Inc., Juniper Networks Inc., Mobixell Networks Inc., Flash Networks Inc., Huawei Technologies Co. Ltd., Nokia Siemens Networks, Propel Software Corporation, Akamai Technologies, Circadence,  Limelight Networks Inc, and Yottaa Inc.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

• North America 
• Asia Pacific 
• Europe
• Rest of the World  

This report provides comprehensive analysis of 

• Market growth drivers 
• Factors limiting market growth
• Current market trends 
• Market structure
• Market projections for upcoming years 

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

North America 

Asia Pacific 

Europe

Rest of the World  

This report provides comprehensive analysis of 

Market growth drivers 

Factors limiting market growth

Current market trends 

Market structure

Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

» Read More...